Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Postive vote from FDA Advisory Committee for Fampridine-SR 10

Acorda Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to 1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated substantial evidence of effectiveness as a treatment to improve walking in people with multiple sclerosis (MS) and voted 10 to 2 (1 abstention) that it is clinically meaningful and can be safe for use.

15 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiated diagnosis from blood samples for lung cancer and multiple sclerosis.

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

It is illegal in the state of California to unsafely dispose of "sharps" (medical waste such as needles and syringes) in the home, and thanks to California State Senator Joe Simitian's Senate Bill 486, and contributors from his annual "There Oughta Be A Law" contest, 1 million Californians will not be breaking the law anymore (see http://www.ciwmb.ca.gov/hhw/sharps/).

13 Oct 2009

Female lawmakers shape health care with their own stories

CQ Politics reports that Rep. Mary Jo Kilroy, D-Ohio, is one of several women lawmakers who is using her own history with multiple sclerosis to lobby for changes in the health care system: "As the health care debate rages on, [Kilroy] has decided to use her personal story to help fellow lawmakers understand how important it is to make health care available for all Americans. In a 'Dear Colleague' letter she sent last week, Kilroy told them about her own diagnosis."

12 Oct 2009

PPA bus tour to raise awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Iowa, Southern Illinois, and Southern Indiana throughout the week of October 12 -- 16th at various cities in order to help uninsured and financially-struggling Midwesterners access information on programs that provide prescription medicines for free or nearly free.

12 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

Inclusion of vitamin D values in National Nutrient Database

The next time you run nutritionals using the government's database, you might be pleasantly surprised that some of your favorite foods seem to have received a nutrient boost, virtually overnight.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

New Leaf Brands, a wholly owned subsidiary of Baywood International, Inc. (OTCBB: BAYW) ("Company"), today announced that the Company will sponsor a participating team in the Multiple Sclerosis/Tappan Zee Bike Ride taking place on Sunday, October 18, 2009 in Tarrytown, New York.

8 Oct 2009

Global pharmaceutical market to grow by 4 - 6 percent: IMS Health

IMS Health reported today that the value of the global pharmaceutical market in 2010 is expected to grow 4 - 6 percent on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the U.S. market.

8 Oct 2009

Scientists make significant advance towards a solution for neuronal repair

The repair of damaged nerve cells is a major problem in medicine today. A new study by researchers at the Montreal NeurologicaI Institute and Hospital (The Neuro) and McGill University, is a significant advance towards a solution for neuronal repair.

8 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

MD Biosciences' new location increases capacity for in vitro services and product development

MD Biosciences (MDB), a contract research organization offering pre-clinical services and products in support of drug discovery for inflammatory and neurological diseases, relocated its U.S. office from 1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on October 3, 2009.

6 Oct 2009

Multiple Sclerosis Association of America receives National Health Information Awards

The Multiple Sclerosis Association of America (MSAA) received four communications awards, which included two APEX Awards and two National Health Information Awards.

5 Oct 2009

Myocardial and neurological effects of Tβ4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on the results of several important research programs with Thymosin beta 4 (Tβ4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

5 Oct 2009

National experts to address epilepsy disorder

The Epilepsy Foundation of Minnesota is partnering with Mayo Clinic to host a regional patient education conference called “Living with Seizures: Today & Tomorrow.” The regional conference will feature national experts in epilepsy, panel discussions and breakout sessions that include the following topics:

5 Oct 2009